Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Camila Xu -- 3462 2022-11-09 01:47:05

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. Discovery and Development of Non-nucleoside Reverse-transcriptase Inhibitors. Encyclopedia. Available online: https://encyclopedia.pub/entry/33577 (accessed on 11 October 2026).
HandWiki. Discovery and Development of Non-nucleoside Reverse-transcriptase Inhibitors. Encyclopedia. Available at: https://encyclopedia.pub/entry/33577. Accessed October 11, 2026.
HandWiki. "Discovery and Development of Non-nucleoside Reverse-transcriptase Inhibitors" Encyclopedia, https://encyclopedia.pub/entry/33577 (accessed October 11, 2026).
HandWiki. (2022, November 09). Discovery and Development of Non-nucleoside Reverse-transcriptase Inhibitors. In Encyclopedia. https://encyclopedia.pub/entry/33577
HandWiki. "Discovery and Development of Non-nucleoside Reverse-transcriptase Inhibitors." Encyclopedia. Web. 09 November, 2022.
Discovery and Development of Non-nucleoside Reverse-transcriptase Inhibitors
Edit
The content is sourced from: https://handwiki.org/wiki/Chemistry:Discovery_and_development_of_non-nucleoside_reverse-transcriptase_inhibitors

Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are antiretroviral drugs used in the treatment of human immunodeficiency virus (HIV). NNRTIs inhibit reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of HIV. RT is one of the most popular targets in the field of antiretroviral drug development. Discovery and development of NNRTIs began in the late 1980s and in the end of 2009 four NNRTI had been approved by regulatory authorities and several others were undergoing clinical development. Drug resistance develops quickly if NNRTIs are administered as monotherapy and therefore NNRTIs are always given as part of combination therapy, the highly active antiretroviral therapy (HAART).

antiretroviral therapy antiretroviral drugs antiretroviral drug

References

  1. "Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations". Journal of Molecular Biology 388 (3): 644–58. May 2009. doi:10.1016/j.jmb.2009.03.037. PMID 19324058.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2744402
  2. "Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV". International Journal of Antimicrobial Agents 33 (4): 307–20. April 2009. doi:10.1016/j.ijantimicag.2008.10.010. PMID 19108994.  https://dx.doi.org/10.1016%2Fj.ijantimicag.2008.10.010
  3. "Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors". Proceedings of the National Academy of Sciences of the United States of America 99 (22): 14410–5. October 2002. doi:10.1073/pnas.222366699. PMID 12386343. Bibcode: 2002PNAS...9914410R.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=137897
  4. "Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead". Journal of Controlled Release 138 (1): 2–15. August 2009. doi:10.1016/j.jconrel.2009.05.007. PMID 19445981.  https://dx.doi.org/10.1016%2Fj.jconrel.2009.05.007
  5. "Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009)". Antiviral Research 85 (1): 75–90. January 2010. doi:10.1016/j.antiviral.2009.09.008. PMID 19781578.  https://dx.doi.org/10.1016%2Fj.antiviral.2009.09.008
  6. "Reverse transcription of the HIV-1 pandemic". FASEB Journal 21 (14): 3795–808. December 2007. doi:10.1096/fj.07-8697rev. PMID 17639073.  https://dx.doi.org/10.1096%2Ffj.07-8697rev
  7. "Novel HIV-1 reverse transcriptase inhibitors". Virus Research 134 (1–2): 171–85. June 2008. doi:10.1016/j.virusres.2008.01.003. PMID 18308412.  https://dx.doi.org/10.1016%2Fj.virusres.2008.01.003
  8. "The search for potent, small molecule NNRTIs: A review". Bioorganic & Medicinal Chemistry 17 (16): 5744–62. August 2009. doi:10.1016/j.bmc.2009.06.060. PMID 19632850.  https://dx.doi.org/10.1016%2Fj.bmc.2009.06.060
  9. "Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors". Progress in Biophysics and Molecular Biology 88 (2): 209–31. June 2005. doi:10.1016/j.pbiomolbio.2004.07.001. PMID 15572156.  https://dx.doi.org/10.1016%2Fj.pbiomolbio.2004.07.001
  10. "Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives". Bioorganic & Medicinal Chemistry Letters 15 (20): 4451–5. October 2005. doi:10.1016/j.bmcl.2005.07.046. PMID 16115762.  https://dx.doi.org/10.1016%2Fj.bmcl.2005.07.046
  11. "Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex". Antiviral Research 81 (1): 47–55. January 2009. doi:10.1016/j.antiviral.2008.09.008. PMID 18984007.  https://dx.doi.org/10.1016%2Fj.antiviral.2008.09.008
  12. "Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies". European Journal of Pharmaceutics and Biopharmaceutics 70 (3): 853–60. November 2008. doi:10.1016/j.ejpb.2008.06.030. PMID 18657611.  https://dx.doi.org/10.1016%2Fj.ejpb.2008.06.030
  13. "Dawn of non-nucleoside inhibitor-based anti-HIV microbicides". The Journal of Antimicrobial Chemotherapy 57 (3): 411–23. March 2006. doi:10.1093/jac/dki464. PMID 16431862.  https://dx.doi.org/10.1093%2Fjac%2Fdki464
  14. "Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors". Virus Research 134 (1–2): 147–56. June 2008. doi:10.1016/j.virusres.2008.01.002. PMID 18372072.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2745993
  15. "Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence". Nucleic Acids Research 42 (18): 11687–96. October 2014. doi:10.1093/nar/gku819. PMID 25232099.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4191400
  16. "Antiviral drug discovery and development: where chemistry meets with biomedicine". Antiviral Research 67 (2): 56–75. August 2005. doi:10.1016/j.antiviral.2005.05.001. PMID 16046240.  https://dx.doi.org/10.1016%2Fj.antiviral.2005.05.001
  17. "Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU)". Bioorganic & Medicinal Chemistry Letters 11 (17): 2225–8. September 2001. doi:10.1016/S0960-894X(01)00410-3. PMID 11527703.  https://dx.doi.org/10.1016%2FS0960-894X%2801%2900410-3
  18. "Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance". Journal of Molecular Biology 284 (2): 313–23. November 1998. doi:10.1006/jmbi.1998.2171. PMID 9813120.  https://dx.doi.org/10.1006%2Fjmbi.1998.2171
  19. "Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant". Journal of Molecular Biology 264 (5): 1085–100. December 1996. doi:10.1006/jmbi.1996.0698. PMID 9000632.  https://dx.doi.org/10.1006%2Fjmbi.1996.0698
  20. "Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues". Bioorganic & Medicinal Chemistry Letters 11 (17): 2229–34. September 2001. doi:10.1016/S0960-894X(01)00411-5. PMID 11527704.  https://dx.doi.org/10.1016%2FS0960-894X%2801%2900411-5
  21. "Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV". Clinical Therapeutics 31 (4): 692–704. April 2009. doi:10.1016/j.clinthera.2009.04.020. PMID 19446143.  https://dx.doi.org/10.1016%2Fj.clinthera.2009.04.020
  22. http://www.tibotec.com/bgdisplay.jhtml?itemname=HIV_tmc278
  23. "Approval of Edurant (rilpivirine), a new NNRTI, for the Treatment of HIV in Treatment Naive Patients" (Press release). Food and Drug Administration. May 20, 2011. Retrieved October 19, 2017. https://aidsinfo.nih.gov/news/902/approval-of-edurant--rilpivirine---a-new-nnrti--for-the-treatment-of-hiv-in-treatment-naive-patients---may-20--2011
  24. "[Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR]" (in Spanish). Enfermedades Infecciosas y Microbiologia Clinica 31 Suppl 2: 20–9. June 2013. doi:10.1016/S0213-005X(13)70139-3. PMID 24252530.  https://dx.doi.org/10.1016%2FS0213-005X%2813%2970139-3
  25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf
  26. "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination" (Press release). Food and Drug Administration. August 10, 2011. Retrieved October 19, 2017. https://aidsinfo.nih.gov/news/909/approval-of-complera--emtricitabine-rilpivirine-tenofovir-df-fixed-dose-combination---august-10--2011
  27. http://www.ardebio.com/ http://www.ardeabio.com/viral.html
  28. "AstraZeneca to acquire Ardea Biosciences for $1 billion (Net of existing cash) including lead product lesinurad in Phase III development for gout". https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-to-acquire-Ardea-Biosciences-for-1-billion-23042012.html. 
  29. [1]
  30. http://www.hivandhepatitis.com/ http://www.hivandhepatitis.com/hiv-aids/hiv-aids-topics/hiv-treatment/3963-viiv-announces-halt-to-lersivirine-development
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 1.9K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 09 Nov 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback